Synergy Pharmaceuticals Presents Poster on Novel Mechanism of Action of SP-333, an Agonist of Guanylate Cyclase-C for Treatment of Ulcerative Colitis

Synergy Pharmaceuticals Presents Poster on Novel Mechanism of Action of SP-333, an Agonist of Guanylate Cyclase-C for Treatment of Ulcerative Colitis

[at noodls] – Scientific Poster Presentation at 2012 Advances in IBD Conference NEW YORK, Dec. 14, 2012 — Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and … more

View todays social media effects on SGYP

View the latest stocks trending across Twitter. Click to view dashboard

See who Synergy is hiring next, click here to view

Share this post